Skip to main content
25kviews
Editorial21 April 2026
Editorial: The microbiome in cancer therapy response
Elizabeth M. Park, Liza Makowskiand Katherine L. Cook

This Research Topic brings together reviews, methodological advances, and original research that collectively examine how microbiome-driven processes intersect with cancer immunity, metabolism, and therapeutic response. Rather than focusing on a single cancer type or intervention, these contributions highlight shared biological principles and experimental approaches that are shaping microbiome-informed oncology.A central theme across this Topic is the interaction between the microbiome and anti-tumor immunity. One review by El-Derby et al. introduces immune-reactive tumor organoids as an innovative ex vivo platform to investigate how microbial metabolites influence cancer immunity and immunotherapeutic efficacy 10 . By incorporating tumor cells, immune components, and microbiome-derived factors, this system addresses key limitations of conventional in vitro models and provides a tractable approach for patient-specific mechanistic studies. The application of such platforms represents an important step toward personalized assessment of microbiome-immunetumor interactions and treatment prediction. Collectively, the articles in this Research Topic position the microbiome-immunity-metabolism axis as a central regulator of cancer biology including both cancer risk and progression to therapeutic response. These contributions emphasize the context-dependent nature of microbiome effects and the necessity of integrative, mechanistically informed approaches. Continued progress will rely on leveraging advanced experimental models, standardized methodologies, and inclusive research strategies to translate microbiome insights into effective, equitable cancer therapies.

1,192 views

REVIEW
5 December 2025
Understanding the role of oral and vaginal microbiomes in HPV-related cervical, head, and neck cancers: knowledge gaps and feasibility in Sub-Saharan Africa
Hélène Eya Kamassa, 5 more and Yaw Bediako

3,407 views

2 citations

ORIGINAL RESEARCH
28 July 2025
Obesity reprograms the normal pancreas and pancreatic cancer microbiome in mice and humans
Raquel Santana da Cruz, 6 more and Sonia de Assis
Obesity reprograms the normal pancreas and pancreatic cancer microbiome in mice and humans
IntroductionPancreatic ductal adenocarcinoma (PDAC) is an aggressive form of pancreatic cancer, with overall 5-year survival rates of about 8%. Obesity (and underlying metabolic dysfunction) is estimated to account for up to 50% of all PDACs. Microbial communities can be modulated by obesity and exert biological effects on tissues they colonize as well as distant sites. Recent studies showed that tumors, including PDAC, harbor a microbiome that is able to regulate cancer outcomes such as tumor progression, response to therapy and overall survival. Yet, it is not understood whether patient’s characteristics impact this relationship.MethodsWe examined the influence of obesity (defined by body weight in mice or body mass index [BMI] in humans) on the normal and cancerous pancreas microbiome in mice and humans using 16S sequencing.ResultsOverall, we observed that diet-induced obesity accelerated PDAC progression in the KC mouse model of PDAC. We also detected an obesity-induced decrease in the microbial abundance of the normal or cancerous pancreas. Obesity modified the bacterial community composition in the normal pancreas and PDAC of both mice and humans. Further, obese animals and humans each had a distinctive pancreatic microbiome signature with specific bacterial phylum, genus and species compared to controls. Notably, both the normal mouse pancreas and human PDAC showed an obesity-induced decrease in Pseudomonadota phylum. We also found that the presence of cancer by itself reduced microbial diversity in both the pancreas as well the intestinal microbiota. This reduction in microbial richness was further exacerbated by obesity. Finally, we observed that obesity increased inflammatory cytokines and altered the tumor immune infiltrate in humans and mice.DiscussionFurther investigation of obesity-driven microbial differences in the pancreas could provide important insights for personalized treatments for PDAC patients.

2,587 views

4 citations

Immune-reactive tumor organoids system to determine the effects of microbial metabolites on cancer immunity and immunotherapies
Immunotherapies are a revolutionary approach to treating cancer by utilizing the body’s immune system to target and combat cancer cells. This approach offers promising alternatives to traditional chemotherapies. Its potential to induce long-lasting remissions and specificity for cancer cells, which minimizes side effects, makes it a cutting-edge treatment with tremendous potential. With the increase of the clinical usage of immunotherapy, evidence emerges of the microbiome’s impact on both tumor growth and response to immunotherapy. The proposed involvement of the microbiome can change treatment efficacy by altering drug metabolism and reshaping the immune system response. Understanding the specific interactions between tumor cells, immune cells, and the microbiome is a critical step in the advancement of immunotherapy. To study the complex interaction between cancer immunity and the microbiome, various preclinical in vivo and in vitro models have been developed. We have recently described the use of an ex vivo preclinical model for anti-cancer treatment outcome prediction –tumor tissue equivalents (organoids). Specifically, immune-reactive tumor organoids are proposed as a novel tool for understanding how the microbiome influences cancer immunity and immunotherapy. More importantly, this platform can utilize patient samples to dissect patient-specific elements regulating cancer immune response and microbiome influence. This review presents the rationale for using the immune-reactive tumor organoids model to study the interactions between the microbiome and cancer immunotherapy. It will discuss available components of the model and analyze their interplay, summarize relevant experimental data, and assess their validity. Additionally, it explores the potential of immune-reactive organoids for personalized treatment approaches. Understanding the microbiome’s role in immunotherapy outcomes will lead to transformative cancer treatment via a simple change of diet or other microbiome manipulations. Ongoing research on microbiome-cancer interactions utilizing the described model systems will lead to innovative treatment strategies and improved patient outcomes.

3,103 views

3 citations

ORIGINAL RESEARCH
13 March 2024
Effect of Bacillus subtilis BS-Z15 metabolite mycosubtilin on body weight gain in mice
Jun Yang, 9 more and Hui-Xin Zhao

2,829 views

1 citations